Table 5

Treatment characteristics of respondents with Crohn's disease and Ulcerative colitis.

Treatments

CD n (%)

UC n (%)

95% CI for difference (P value)


PO 5ASA

956 (54%)

672 (74%)

-23.7 to -16.4 (<0.001)

Topical Steroids/5ASA

183 (10%)

391 (43%)

-36.1 to -29.1 (<0.001)

PO Steroids

623 (35%)

259 (28%)

2.8 to 10.2 (0.001)

6 MP/Azathioprine

424 (24%)

109 (12%)

8.9 to 14.7 (<0.001)

IV Steroids

90 (5%)

41 (5%)

-1.1 to 2.2 (0.571)

Infliximab

99 (6%)

7 (1%)

3.6 to 6.0 (<0.001)


PO: Per os 5ASA: 5-Aminosalicylates 6MP: 6-Mercaptopurince IV: Intravenous

Hilsden et al. BMC Gastroenterology 2003 3:10   doi:10.1186/1471-230X-3-10

Open Data